Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | LDLR | P01130 | 1/20 | 0.55 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 6/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 7/20 | 0.49 |
| ▸ | FLT3 | P36888 | 4/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | MARK3 | P27448 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27387276 | 1.00 | KIT (0.55) | KITLDLRPCSK9JAK2JAK3 | |
| SCHEMBL27387222 | 1.00 | KIT (0.55) | KITLDLRPCSK9JAK2JAK3 | |
| SCHEMBL30788197 | 1.00 | KIT (0.55) | KITLDLRPCSK9JAK2JAK3 | |
| SCHEMBL27387226 | 0.91 | JAK2 (0.62) | KITJAK2JAK3FLT3PLK4 | |
| SCHEMBL30788201 | 0.82 | JAK2 (0.65) | KITJAK2JAK3CDK2FLT3 | |
| SCHEMBL27387206 | 0.82 | JAK2 (0.65) | KITJAK2JAK3CDK2FLT3 | |
| SCHEMBL27387208 | 0.82 | JAK2 (0.65) | KITJAK2JAK3CDK2FLT3 | |
| SCHEMBL30788209 | 0.82 | JAK2 (0.65) | KITJAK2JAK3CDK2FLT3 | |
| SCHEMBL34463169 | 0.82 | JAK2 (0.65) | KITLDLRPCSK9JAK2JAK3 | |
| SCHEMBL27387228 | 0.80 | JAK2 (0.67) | KITJAK2JAK3CDK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | H LEE MOFFITT CANCER CT & RES (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2024035771-A2 | ULK3 INHIBITORS AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103455-A1 | ULK3 INHIBITORS AND USES THEREOF | ULK3, ULK1, ULK2 | KIT 1917/4885LDLR 1853/4885PCSK9 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.